Pharmaceutical Contract Manufacturing Market Size, Share, Demands, Key Players Analysis, Growth Rate and Forecasts to 2028

The global pharmaceutical contract development and manufacturing market size is projected to reach USD 258.3 billion by 2028 from USD 176.5 billion in 2023, at a CAGR of 7.9% during the forecast period. Factors such as increasing demand for generics due to their low cost and the looming patent expiry of blockbuster medications have pushed companies to focus on core functions, supporting the demand for CDMO services, and driving the market growth at a faster pace.

Download a FREE Sample Report at https://www.reportsnreports.com/contacts/requestsample.aspx?name=2439858

The pharmaceutical contract manufacturing market refers to the outsourcing of drug manufacturing processes to third-party organizations, which offer specialized services such as drug development, formulation, testing, and packaging. Pharmaceutical contract manufacturing helps drug companies to reduce manufacturing costs, improve efficiency, and focus on core competencies such as research and development.

Based on the type of manufacturing, the pharmaceutical contract manufacturing market is segmented into active pharmaceutical ingredient (API) manufacturing and finished dosage form (FDF) manufacturing. The API manufacturing segment is expected to hold the largest market share during the forecast period, owing to the increasing demand for generic drugs and the growing need for cost-effective drug manufacturing.

Geographically, the pharmaceutical contract manufacturing market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is expected to hold the largest market share during the forecast period, owing to the presence of a large number of pharmaceutical companies and contract manufacturing organizations in the region. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing investments in healthcare infrastructure, the rising demand for affordable medicines, and the growing focus on research and development activities in emerging economies such as China and India.

Lists of Companies Profiled in the Report:

Thermo Fisher Scientific, Inc. (US)
Catalent, Inc. (US)
Lonza Group (Switzerland)
AbbVie, Inc. (US)
WuXi AppTec (China)
Evonik Industries AG (Germany)
Samsung Biologics. (South Korea)
Boehringer Ingelheim International GmbH. (Germany)
Siegfried Holding AG (Switzerland)
Piramal Pharma Solutions (India)
Recipharm AB. (Sweden)
Eurofins Scientific (Luxembourg)
FUJIFILM Holdings Corporation (Japan)
Almac Group (UK)
Vetter Pharma (Germany)
Delpharm Holdings (France)
Yuhan Corporation (South Korea)
Curia Global, Inc. (US)
Charles River Laboratories. (US)
Lannett Company, Inc. (US)
Cambrex Corporation. (US)
FAMAR Healthcare Services (France)
Biocon Limited (India)
Sai Life Sciences Limited (India)
PCI Pharma Services (US).

Direct Purchase of the Global Pharmaceutical Contract Manufacturing Market Research Report at https://www.reportsnreports.com/purchase.aspx?name=2439858

These companies are focusing on expanding their manufacturing capabilities, investing in research and development activities, and entering into strategic partnerships to enhance their market presence and stay competitive in the market.

+ 1 347 333 3771
sales@reportsandreports.com

ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

This release was published on openPR.